10 results on '"Pullen,Rachel"'
Number of results to display per page
Search Results
2. Identification of key opportunities for optimising the management of high-risk COPD patients in the UK using the CONQUEST quality standards: an observational longitudinal study
- Author
-
Halpin, David M.G., Dickens, Andrew P., Skinner, Derek, Murray, Ruth, Singh, Mukesh, Hickman, Katherine, Carter, Victoria, Couper, Amy, Evans, Alexander, Pullen, Rachel, Menon, Shruti, Morris, Tamsin, Muellerova, Hana, Bafadhel, Mona, Chalmers, James, Devereux, Graham, Gibson, Martin, Hurst, John R., Jones, Rupert, Kostikas, Konstantinos, Quint, Jennifer, Singh, Dave, van Melle, Marije, Wilkinson, Tom, and Price, David
- Published
- 2023
- Full Text
- View/download PDF
3. CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients
- Author
-
Alves,Luis, Pullen,Rachel, Hurst,John R, Miravitlles,Marc, Carter,Victoria, Chen,Rongchang, Couper,Amy, Dransfield,Mark, Evans,Alexander, Hardjojo,Antony, Jones,David, Jones,Rupert, Kerr,Margee, Kostikas,Konstantinos, Marshall,Jonathan, Martinez,Fernando, van Melle,Marije, Murray,Ruth, Muro,Shigeo, Nordon,Clementine, Pollack,Michael, Price,Chris, Sharma,Anita, Singh,Dave, Winders,Tonya, Price,David B, Alves,Luis, Pullen,Rachel, Hurst,John R, Miravitlles,Marc, Carter,Victoria, Chen,Rongchang, Couper,Amy, Dransfield,Mark, Evans,Alexander, Hardjojo,Antony, Jones,David, Jones,Rupert, Kerr,Margee, Kostikas,Konstantinos, Marshall,Jonathan, Martinez,Fernando, van Melle,Marije, Murray,Ruth, Muro,Shigeo, Nordon,Clementine, Pollack,Michael, Price,Chris, Sharma,Anita, Singh,Dave, Winders,Tonya, and Price,David B
- Abstract
Luis Alves,1 Rachel Pullen,2 John R Hurst,3 Marc Miravitlles,4 Victoria Carter,5 Rongchang Chen,6 Amy Couper,2 Mark Dransfield,7 Alexander Evans,5 Antony Hardjojo,2 David Jones,5 Rupert Jones,8 Margee Kerr,5 Konstantinos Kostikas,9 Jonathan Marshall,10 Fernando Martinez,11 Marije van Melle,5 Ruth Murray,5 Shigeo Muro,12 Clementine Nordon,10 Michael Pollack,13 Chris Price,5 Anita Sharma,14 Dave Singh,15 Tonya Winders,16 David B Price2 1EPIUnit - Epidemiology Research Unit, ITR - Laboratory for Integrative and Translational Research in Population Health, Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal; 2Observational and Pragmatic Research Institute, Singapore, Singapore; 3UCL Respiratory, University College London, London, UK; 4Pneumology Dept, Hospital Universitari Vall dâHebron, Vall dâHebron Institut de Recerca (VHIR), Vall dâHebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain; 5Optimum Patient Care, Cambridge, UK; 6Key Laboratory of Respiratory Disease of Shenzhen, Shenzhen Institute of Respiratory Disease, Shenzhen Peopleâs Hospital (Second Affiliated Hospital of Jinan University, First Affiliated Hospital of South University of Science and Technology of China), Shenzhen, Guangdong, Peopleâs Republic of China; 7Division of Pulmonary, Allergy, and Critical Care Medicine, Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA; 8Research and Knowledge Exchange, Plymouth Marjon University, Plymouth, UK; 9Respiratory Medicine Department, University of Ioannina School of Medicine, Ioannina, Greece; 10BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK; 11New York-Presbyterian Weill Cornell Medical Center, New York, NY, USA; 12Department of Respiratory Medicine, Nara Medical University, Nara, Japan; 13BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA; 14Platinum Medical Centre, Chermside, QLD, Australia; 15Division of Infection, Immunity & Respiratory
- Published
- 2022
4. CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients
- Author
-
Alves, Luis, primary, Pullen, Rachel, additional, Hurst, John R, additional, Miravitlles, Marc, additional, Carter, Victoria, additional, Chen, Rongchang, additional, Couper, Amy, additional, Dransfield, Mark, additional, Evans, Alexander, additional, Hardjojo, Antony, additional, Jones, David, additional, Jones, Rupert, additional, Kerr, Margee, additional, Kostikas, Konstantinos, additional, Marshall, Jonathan, additional, Martinez, Fernando, additional, van Melle, Marije, additional, Murray, Ruth, additional, Muro, Shigeo, additional, Nordon, Clementine, additional, Pollack, Michael, additional, Price, Chris, additional, Sharma, Anita, additional, Singh, Dave, additional, Winders, Tonya, additional, and Price, David B, additional
- Published
- 2022
- Full Text
- View/download PDF
5. CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care
- Author
-
Pullen, Rachel, primary, Miravitlles, Marc, additional, Sharma, Anita, additional, Singh, Dave, additional, Martinez, Fernando, additional, Hurst, John R, additional, Alves, Luis, additional, Dransfield, Mark, additional, Chen, Rongchang, additional, Muro, Shigeo, additional, Winders, Tonya, additional, Blango, Christopher, additional, Muellerova, Hana, additional, Trudo, Frank, additional, Dorinsky, Paul, additional, Alacqua, Marianna, additional, Morris, Tamsin, additional, Carter, Victoria, additional, Couper, Amy, additional, Jones, Rupert, additional, Kostikas, Konstantinos, additional, Murray, Ruth, additional, and Price, David B, additional
- Published
- 2021
- Full Text
- View/download PDF
6. CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care
- Author
-
Pullen,Rachel, Miravitlles,Marc, Sharma,Anita, Singh,Dave, Martinez,Fernando, Hurst,John R, Alves,Luis, Dransfield,Mark, Chen,Rongchang, Muro,Shigeo, Winders,Tonya, Blango,Christopher, Muellerova,Hana, Trudo,Frank, Dorinsky,Paul, Alacqua,Marianna, Morris,Tamsin, Carter,Victoria, Couper,Amy, Jones,Rupert, Kostikas,Konstantinos, Murray,Ruth, Price,David B, Pullen,Rachel, Miravitlles,Marc, Sharma,Anita, Singh,Dave, Martinez,Fernando, Hurst,John R, Alves,Luis, Dransfield,Mark, Chen,Rongchang, Muro,Shigeo, Winders,Tonya, Blango,Christopher, Muellerova,Hana, Trudo,Frank, Dorinsky,Paul, Alacqua,Marianna, Morris,Tamsin, Carter,Victoria, Couper,Amy, Jones,Rupert, Kostikas,Konstantinos, Murray,Ruth, and Price,David B
- Abstract
Rachel Pullen, 1, 2 Marc Miravitlles, 3 Anita Sharma, 4 Dave Singh, 5 Fernando Martinez, 6 John R Hurst, 7 Luis Alves, 8, 9 Mark Dransfield, 10 Rongchang Chen, 11 Shigeo Muro, 12 Tonya Winders, 13 Christopher Blango, 14 Hana Muellerova, 15 Frank Trudo, 16 Paul Dorinsky, 17 Marianna Alacqua, 15, 18 Tamsin Morris, 19 Victoria Carter, 1, 2 Amy Couper, 1, 2 Rupert Jones, 20 Konstantinos Kostikas, 1, 21 Ruth Murray, 1 David B Price 1, 2, 22 1Observational and Pragmatic Research Institute, Singapore, Singapore; 2Optimum Patient Care, Cambridge, UK; 3Pneumology Dept, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain; 4Platinum Medical Centre, Chermside, QLD, Australia; 5Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK; 6New York-Presbyterian Weill Cornell Medical Center, New York, NY, USA; 7UCL Respiratory, University College London, London, UK; 8EPI Unit, Institute of Public Health, University of Porto, Porto, Portugal; 9Laboratory for Integrative and Translational Research in Population Health (ITR), Porto, Portugal; 10Division of Pulmonary, Allergy, and Critical Care Medicine, Lung Health Center, University of Alabama at Birmingham, Birmingham, AL, USA; 11Key Laboratory of Respiratory Disease of Shenzhen, Shenzhen Institute of Respiratory Disease, Shenzhen People’s Hospital (Second Affiliated Hospital of Jinan University, First Affiliated Hospital of South University of Science and Technology of China), Shenzhen, People’s Republic of China; 12Department of Respiratory Medicine, Nara Medical University, Nara, Japan; 13USA & Global Allergy & Airways Patient Platform, Vienna, Austria; 14Janssen Pharmaceutical Companies of Johnson & Johnson, Philadelphia, PA, USA; 15Astra
- Published
- 2021
7. Strategies that promote sustainability in quality improvement activities for chronic disease management in healthcare settings:A Practical Perspective
- Author
-
Evans, Alexander, Soremekun, Seyi, Stanley, Brooklyn, Appiagyei, Francis, Couper, Amy, Taylor, Oliver, Le, Thao, Pullen, Rachel, Jones, Sophie, Carter, Victoria, Price, Chris, Jones, Rupert, Hancock, Kerry, Bosnic-Anticevich, Sinthia, Ryan, Dermot, and Price, David
- Abstract
Healthcare providers recognise the value of quality improvement (QI) activities that enhance the care received by service users. QI is particularly effective for the management of long-term conditions requiring linked care. However, starting and sustaining QI programmes in practice can be time-consuming and difficult and may produce inconclusive and/or inconsistent results. As a not-for-profit social enterprise, Optimum Patient Care (OPC) has been delivering effective and sustainable QI since 2005 in healthcare systems in several countries.This paper provides a roadmap for the implementation of collaborative QI programmes in a range of settings across three countries. It summarises the barriers we have experienced in the QI cycle and solutions we have identified in our history of working with healthcare providers to deliver QI programmes in primary and secondary care. Key lessons include the strategic involvement of partners in the fields of medicine, health IT, data science and epidemiology, to harness, understand and act on the insights gained from patient and practice electronic health data (EHR) alongside crucial input from patients and practicing clinicians themselves.QI aims resource-poor healthcare providers to increase the precision of identifying key patient groups requiring further follow-up – such as those at risk of worsening health outcomes using risk prediction tools. Parallel goals are to increase the proportion of patients receiving prompt and appropriate treatment and to increase patient engagement. We achieve this by providing customised software tools and disease management algorithms to our healthcare partners to allow for automation of aspects of QI that have traditionally involved a manual process. Sharing our experience of these methods helps to embed a sustainable programme of QI in many systems in varied settings.
- Published
- 2020
8. Cost-effectiveness of a supplementary class-based exercise program in the treatment of knee osteoarthritis
- Author
-
Richardson, Gerry, primary, Hawkins, Neil, additional, McCarthy, Christopher James, additional, Mills, Pauline Mary, additional, Pullen, Rachel, additional, Roberts, Christopher, additional, Silman, Alan, additional, and Oldham, Jacqueline Ann, additional
- Published
- 2006
- Full Text
- View/download PDF
9. MAIL BAG.
- Author
-
Pullen, Rachel, Goode, Tyler, Craig, Stearn, Brandon, and Faulk, Stacy
- Abstract
Several letters to the editor are presented including one regarding the reader's desire to buy a Redline Syntax bicycle, second concerning the reader's admiration for bicycle rider Garrett Reynolds, and another which discusses the reader's involvement in bicycle motocross (BMX).
- Published
- 2015
10. Exacerbation history and blood eosinophil count prior to diagnosis of COPD and risk of subsequent exacerbations.
- Author
-
Halpin DMG, Healey H, Skinner D, Carter V, Pullen R, and Price D
- Subjects
- Humans, Male, Female, Aged, Middle Aged, Leukocyte Count, Adrenal Cortex Hormones therapeutic use, Anti-Bacterial Agents therapeutic use, Hospitalization statistics & numerical data, Risk Factors, Severity of Illness Index, Aged, 80 and over, Pulmonary Disease, Chronic Obstructive blood, Pulmonary Disease, Chronic Obstructive diagnosis, Eosinophils, Disease Progression
- Abstract
Background: Prior exacerbation history is used to guide initial maintenance therapy in COPD; however, the recommendations were derived from patients already diagnosed and treated., Methods: We assessed the rates of moderate ( i.e. treated with antibiotics and/or systemic corticosteroids) and severe ( i.e. hospitalised) exacerbations in the year following diagnosis in patients newly diagnosed with COPD according to their prior history of exacerbations, blood eosinophil count (BEC) and whether maintenance therapy was started. Data were extracted from the Optimum Patient Care Research Database., Results: 73 189 patients were included. 61.9% had no exacerbations prior to diagnosis, 21.5% had 1 moderate, 16.5% had ≥2 moderate and 0.3% had ≥1 severe. 50% were started on maintenance therapy. In patients not started on maintenance therapy the rates of moderate exacerbations in the year after diagnosis in patients with no, 1 moderate, ≥2 moderate and ≥1 severe prior exacerbations were 0.34 (95% CI 0.33-0.35), 0.59 (95% CI 0.56-0.61), 1.18 (95% CI 1.14-1.23) and 1.21 (95% CI 0.73-1.69), respectively. Similar results were seen in patients started on maintenance therapy. BEC did not add significantly to the prediction of future exacerbation risk., Conclusions: A single moderate exacerbation in the year prior to diagnosis increases the risk of subsequent exacerbations, and more frequent or severe exacerbations prior to diagnosis are associated with a higher risk., Competing Interests: Conflict of interest: D.M.G. Halpin has received sponsorship to attend international meetings, and honoraria for lecturing, attending advisory boards and preparing educational materials from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Inogen, Meanrini, Novartis and Sanofi. H. Healey, D. Skinner, V. Carter and R. Pullen are employees of the Observational and Pragmatic Research Institute. D. Price has advisory board membership with AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme and Thermo Fisher, consultancy agreements with Airway Vista Secretariat, AstraZeneca, Boehringer Ingelheim, Chiesi, EPG Communication Holdings Ltd, FIECON Ltd, Fieldwork International, GlaxoSmithKline, Mylan, Mundipharma, Novartis, OM Pharma SA, PeerVoice, Phadia AB, Spirosure Inc., Strategic North Limited, Synapse Research Management Partners SL, Talos Health Solutions, Theravance and WebMD Global LLC, grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Novartis, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Theravance and UK National Health Service, payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals and Sanofi Genzyme, payment for travel, accommodation and/or meeting expenses from AstraZeneca, Boehringer Ingelheim, Mundipharma, Mylan, Novartis and Thermo Fisher, stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals, 74% ownership of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 92.61% of Observational and Pragmatic Research Institute Pte Ltd (Singapore), 5% shareholding in Timestamp which develops adherence monitoring technology, is peer reviewer for grant committees of the UK Efficacy and Mechanism Evaluation programme, and Health Technology Assessment, and was an expert witness for GlaxoSmithKline., (Copyright ©The authors 2024.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.